Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1

Journal of Clinical Microbiology

Volumn 46, Issue 4, 2008, Pages 1530-1533

  Åkerlund, Thomas ^a   Persson, Ingela ^a   Unemo, Magnus ^b   Norén, Torbjörn ^b   Svenungsson, Bo ^c   Wullt, Marlene ^d   Burman, Lars G ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; METRONIDAZOLE; PENICILLIN V; PIPERACILLIN PLUS TAZOBACTAM; TOXIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; QUINOLINE DERIVATIVE; REPRESSOR PROTEIN; TCDC PROTEIN, CLOSTRIDIUM DIFFICILE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; DRUG EFFICACY; EPIDEMIC; GENE SEQUENCE; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPOROGENESIS; BACTERIAL SPORE; CLASSIFICATION; DRUG EFFECT; GENETICS; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; PSEUDOMEMBRANOUS COLITIS; RIBOTYPING; VIRULENCE;

CLOSTRIDIUM DIFFICILE;

AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL PROTEINS; CLOSTRIDIUM DIFFICILE; DISEASE OUTBREAKS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; QUINOLINES; REPRESSOR PROTEINS; RIBOTYPING; SPORES, BACTERIAL; VIRULENCE;

EID: 42449157632     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01964-07     Document Type: Article

References (37)

1. Adams, D. A., M. M. Riggs, and C. J. Donskey. 2007. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antmicrob. Agents Chemother. 51:2674-2678.
2. Åkerlund, T., B. Svenungsson, A. Lagergren, and L. G. Burman. 2006. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J. Clin. Microbiol. 44:353-358.
3. Biller, P., B. Shank, L. Lind, M. Brennan, L. Tkatch, G. Killgore, A. Thompson, and L. C. McDonald. 2007. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect. Control Hosp. Epidemiol. 28:198-201.
4. Bourgault, A. M., F. Lamothe, V. G. Loo, L. Poirier, and the CDAD-CSI Study Group. 2006. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada. Antimicrob. Agents Chemother. 50:3473-3475.
5. Curry, S. R., J. W. Marsh, C. A. Muto, M. M. O'Leary, A. W. Pasculle, and L. H. Harrison. 2007. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J. Clin. Microbiol. 45:215-221.
6. Dineen, S. S., A. C. Villapakkam, J. T. Nordman, and A. L. Sonenshein. 2007. Repression of Clostridium difficile toxin gene expression by CodY. Mol. Microbiol. 66:206-219.
7. Freeman, J., S. D. Baines, K. Saxton, and W. H. Wilcox. 2007. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J. Antimicrob. Chemother. 60:83-91.
8. Gaynes, R., D. Rimland, E. Killum, H. K. Lowery, T. M. Johnson II, G. Killgore, and F. C. Tenover. 2004. Outbreak of Clostridium difficile infection in a long-term facility: association with gatifloxacin use. Clin. Infect. Dis. 38:640-645.
9. Gerding, D. N., S. Johnson, L. R. Peterson, M. E. Mulligan, and J. Silva, Jr. 1995. Clostridium difficile-associated diarrhea and colitis. Infect. Control Hosp. Epidemiol. 16:459-477.
10. Hubert, B., V. G. Loo, A. M. Bourgault, L. Poirer, A. Dascal, E. Fortin, M. Dionne, and M. Lorange. 2007. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin. Infect. Dis. 44:238-244.
11. Johnson, S., M. H. Samore, K. A. Farrow, G. E. Killgore, F. C. Tenover, D. Lyras, J. I. Rood, P. DeGirolami, A. L. Baltch, M. E. Rafferty, S. M. Pear, and D. N. Gerding. 1999. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 341:1645-1651.
12. Joseph, R., D. Demeyer, D. Vanrenterghem, R. van den Berg, E. Kuijper, and M. Delmee. 2005. First isolation of Clostridium difficile PCR ribotype 027, toxinotype III in Belgium. Euro. Surveill. 10:E051020.4. www.eurosurveillance.org/ew/2005/051020.asp#4.
13. Karlsson, S., A. Lindberg, L. G. Burman, E. Norin, and T. Åkerlund. 2000. Toxins, butyric acid and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile. Infect. Immun. 68:5881-5888.
14. Karlsson, S., L. G. Burman, and T. Åkerlund. 1999. Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids. Microbiology 145:1683-1693.
15. Kuijper, E. J., B. Coignard, P. Tull, ESCMID Study Group for Clostridium difficile, EU Member States, and the European Centre for Disease Prevention and Control. 2006. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 6(Suppl.):S2-S18.
16. Kuijper, E- J., J. T. van Dissel, and M. H. Wilcox. 2007. Clostridium difficile: changing epidemiology and new treatment options. Curr. Opin. Infect. Dis. 20:376-383.
17. Kuijper, E. J., R. J. van den Berg, S. Debast, C. E. Visser, D. Veenendaal, A. Troelstra, T. van der Kooi, S. van den Hof, and D. W. Notermans. 2006. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg. Infect. Dis. 12:827-830.
18. Loo, V. G., L. Poirier, M. A. Miller, M. Oughton, M. D. Libman, S. Michaud, A. M. Bourgault, T. Nguyen, C. Frenette, M. Kelly, A. Vibien, P. Brassard, S. Fenn, K. Dewar, T. J. Hudson, R. Horn, P. Rene, Y. Monczak, and A. Dascal. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449.
19. MacCannell, D. R., T. J. Louie, D. B. Gregson, M. Laverdiere, A. C. Labbe, F. Laing, and S. Henwick. 2006. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J. Clin. Microbiol. 44:2147-2152.
20. Mani, N., and B. Dupuy. 2001. Regulation of toxin synthesis in Clostridium. difficile by an alternative RNA polymerase sigma factor. Proc. Natl. Acad. Sci. USA 98:5844-5849.
21. Matamouros, S., P. England, and B. Dupuy. 2007. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol. Microbiol. 64:1274-1288.
22. McDonald, L. C., G. E. Killgore, A. Thompson, R. C. Owens, Jr., S. V. Kazakova, S. P. Sambol, S. Johnson, and D. N. Gerding. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
23. Norén, T., T. Åkerlund, E. Bäck, L. Sjöberg, I. Persson, I. Alriksson, and L. G. Burman. 2004. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J. Clin. Microbiol. 42:3635-3643.
24. Norén, T., T. Åkerlund, M. Wullt, L. G. Burman, and M. Unemo. 2007. Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile. Antimicrob. Agents Chemother. 51:1840-1843.
25. Pépin, J., L. Valiquette, M. E. Alary, P. Villemure, A. Pelletier, K. Forget, K. Pepin, and D. Chouinard. 2004. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466-472.
26. Pépin, J., L. Valiquette, and B. Cossette. 2005. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037-1042.
27. Pépin, J., N. Saheb, M. A. Coulombe, M. E. Alary, M. P. Corriveau, S. Authier, M. LeBlanc, G. Rivard, M. Bettez, V. Primeau, M. Nquyen, C. E. Jacob, and L. Lanthier. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1254-1260.
28. Spigaglia, P., and P. Mastrantonio. 2002. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J. Clin. Microbiol. 40:3470-3475.
29. Svenungsson, B., A. Lagergren, E. Ekwall, B. Evengård, K. O. Hedlund, A. Kärnell, S. Löfdahl, L. Svensson, and A. Weintraub. 2000. Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases. Clin. Infect. Dis. 30:770-778.
30. Svenungsson, B., L. G. Burman, K. Jalakas-Pörnull, Å. Lagergren, J. Struwe, and T. Åkerlund. 2003. Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital. J. Clin. Microbiol. 41:4031-4037.
31. Tachon, M., C. Cattoen, K. Blanckaert, I. Poujol, A. Carbonne, F. Barbut, J. C. Petit, and B. Coignard. 2006. First cluster of C. difficile toxinotype III, PCR-ribotype 027 associated disease in France: preliminary report. Euro. Surveill. 11:E060504.1. www.eurosurveillance. org/ew/2006/060504.asp#1.
32. Valiquette, L., B. Cossette, M. P. Garant, H. Diab, and J. Pepin. 2007. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin. Infect. Dis. 45(Suppl.):S112-S121.
33. van Dijck, P., V. Avesani, and M. Delmée. 1996. Genotyping of outbreak-related and sporadic isolates of Clostridium difficile belonging to serogroup C. J. Clin. Microbiol. 34:3049-3055.
34. Warny, M., J. Pepin, A. Fang, G. Killgore, A. Thompson, J. Brazier, E. Frost, and L. C. McDonald. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084.
35. Wullt, M., and I. Odenholt. 2004. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J. Antimicrob. Chemother. 54:211-216.
36. Wullt, M., M. L. Hagslätt, and I. Odenholt. 2003. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand. J. Infect. Dis. 35:365-367.
37. Wullt, M., L. G. Burman, M. H. Laurell, and T. Åkerlund. 2003. Comparison of AP-PCR typing and PCR-ribotyping for estimation of nosocomial transmission of Clostridium difficile. J. Hosp. Infect. 55:124-130.